Christoph Schramm

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4437458/publications.pdf

Version: 2024-02-01

115 papers	7,583 citations	76196 40 h-index	56606 83 g-index
118 all docs	118 docs citations	118 times ranked	8529 citing authors

#	Article	IF	Citations
1	Impact on followâ€up strategies in patients with primary sclerosing cholangitis. Liver International, 2023, 43, 127-138.	1.9	15
2	Reporting standards for primary sclerosing cholangitis using MRI and MR cholangiopancreatography: guidelines from MR Working Group of the International Primary Sclerosing Cholangitis Study Group. European Radiology, 2022, 32, 923-937.	2.3	27
3	Long-term outcome after living donor liver transplantation compared to donation after brain death in autoimmune liver diseases: Experience from the European Liver Transplant Registry. American Journal of Transplantation, 2022, 22, 626-633.	2.6	14
4	The EASLâ€“Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet, The, 2022, 399, 61-116.	6.3	257
5	Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group. Journal of Hepatology, 2022, 76, 841-849.	1.8	64
6	Persistent SOMAtic symptoms ACROSS diseases â€” from risk factors to modification: scientific framework and overarching protocol of the interdisciplinary SOMACROSS research unit (RU 5211). BMJ Open, 2022, 12, e057596.	0.8	33
7	Cross-tissue transcriptome-wide association studies identify susceptibility genes shared between schizophrenia and inflammatory bowel disease. Communications Biology, 2022, 5, 80.	2.0	12
8	Colonisation of bile ducts with Enterococcus sp. associates with the prognosis of Primary Sclerosing Cholangitis. Zeitschrift Fur Gastroenterologie, 2022, 60, .	0.2	0
9	Low antibody titers after second SARS-CoV-2 vaccination in patients with autoimmune hepatitis. Zeitschrift Fur Gastroenterologie, 2022, 60, .	0.2	0
10	Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation. Journal of Hepatology, 2022, 77, 84-97.	1.8	21
11	Circulating microbiome in patients with portal hypertension. Gut Microbes, 2022, 14, 2029674.	4.3	22
12	Autoimmune hepatitis and COVID-19: No increased risk for AIH after vaccination but reduced care. Journal of Hepatology, 2022, 77, 250-251.	1.8	9
13	SARSâ€CoVâ€2 vaccination response in patients with autoimmune hepatitis and autoimmune cholestatic liver disease. United European Gastroenterology Journal, 2022, 10, 319-329.	1.6	27
14	The intestinal and biliary microbiome in autoimmune liver diseaseâ€”current evidence and concepts. Seminars in Immunopathology, 2022, 44, 485-507.	2.8	22
15	Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis. Journal of Hepatology, 2022, 77, 1545-1553.	1.8	33
16	Inflammatory type 2 conventional dendritic cells contribute to murine and human cholangitis. Journal of Hepatology, 2022, 77, 1532-1544.	1.8	5
17	Update of the simplified criteria for autoimmune hepatitis: Evaluation of the methodology for immunoserological testing. Journal of Hepatology, 2021, 74, 312-320.	1.8	31
18	Cell-autonomous hepatocyte-specific GP130 signaling is sufficient to trigger a robust innate immune response in mice. Journal of Hepatology, 2021, 74, 407-418.	1.8	15

#	Article	IF	Citations
19	Aryl Hydrocarbon Receptor Activity in Hepatocytes Sensitizes to Hyperacute Acetaminophen-Induced Hepatotoxicity in Mice. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 371-388.	2.3	11
20	IL-17A/F enable cholangiocytes to restrict T cell-driven experimental cholangitis by upregulating PD-L1 expression. Journal of Hepatology, 2021, 74, 919-930.	1.8	18
21	Altered Gut Microbial Metabolism of Essential Nutrients in Primary Sclerosing Cholangitis. Gastroenterology, 2021, 160, 1784-1798.e0.	0.6	69
22	Efficacy of a Brief, Peer-Delivered Self-management Intervention for Patients With Rare Chronic Diseases. JAMA Psychiatry, 2021, 78, 607.	6.0	8
23	Histological activity despite normal ALT and IgG serum levels in patients with autoimmune hepatitis and cirrhosis. JHEP Reports, 2021, 3, 100321.	2.6	14
24	Single-cell atlas of hepatic T cells reveals expansion of liver-resident naive-like CD4+ T cells in primary sclerosing cholangitis. Journal of Hepatology, 2021, 75, 414-423.	1.8	49
25	The genetic architecture of primary biliary cholangitis. European Journal of Medical Genetics, 2021, 64, 104292.	0.7	18
26	Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis. Journal of Hepatology, 2021, 75, 634-646.	1.8	51
27	Mobile app requirements for patients with rare liver diseases: A single center survey for the ERN RARE-LIVERâ€¬â€¬â€¬. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101760.	0.7	1
28	Oxysterol 7-Î± Hydroxylase (CYP7B1) Attenuates Metabolic-Associated Fatty Liver Disease in Mice at Thermoneutrality. Cells, 2021, 10, 2656.	1.8	10
29	Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2020, 18, 179-187.e6.	2.4	57
30	A System to Determine Risk of Osteoporosis in Patients With Autoimmune Hepatitis. Clinical Gastroenterology and Hepatology, 2020, 18, 226-233.e3.	2.4	15
31	Alterations of the bile microbiome in primary sclerosing cholangitis. Gut, 2020, 69, 665-672.	6.1	80
32	Concise Commentary: Why Cholangioscopy for Indeterminate Biliary Strictures in PSC Is Still Not Good Enough. Digestive Diseases and Sciences, 2020, 65, 1479-1480.	1.1	6
33	Rapid Response to Treatment of Autoimmune Hepatitis Associated With Remission at 6 and 12 Months. Clinical Gastroenterology and Hepatology, 2020, 18, 1609-1617.e4.	2.4	25
34	Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities. Hepatology, 2020, 72, 1253-1266.	3.6	42
35	The Effects of Androgens on T Cells: Clues to Female Predominance in Autoimmune Liver Diseases?. Frontiers in Immunology, 2020, 11, 1567.	2.2	34
36	Long-term outcome in PSC patients receiving azathioprine: Does immunosuppression have a positive effect on survival?. Journal of Hepatology, 2020, 73, 1285-1287.	1.8	3

#	Article	IF	Citations
37	A diseaseâ€specific decline of the relative abundance of Bifidobacterium in patients with autoimmune hepatitis. Alimentary Pharmacology and Therapeutics, 2020, 51, 1417-1428.	1.9	55
38	High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation. Liver International, 2020, 40, 2164-2171.	1.9	16
39	Editorial: gut microbiota profile in patients with autoimmune hepatitisâ€"a clue for adjunctive probiotic therapy? Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 52, 394-395.	1.9	0
40	Longterm Survival After Liver Transplantation for Autoimmune Hepatitis: Results From the European Liver Transplant Registry. Liver Transplantation, 2020, 26, 866-877.	1.3	25
41	Monocytes as Potential Mediators of Pathogenâ€Induced Tâ€Helper 17 Differentiation in Patients With Primary Sclerosing Cholangitis (PSC). Hepatology, 2020, 72, 1310-1326.	3.6	50
42	Gut mycobiome of primary sclerosing cholangitis patients is characterised by an increase of Trichocladium griseum and Candida species. Gut, 2020, 69, 1890-1892.	6.1	25
43	Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis. Journal of Hepatology, 2020, 73, 559-565.	1.8	47
44	Diagnosis and treatment of primary biliary cholangitis. United European Gastroenterology Journal, 2020, 8, 667-674.	1.6	20
45	Bone microarchitecture in patients with autoimmune hepatitis. Journal of Bone and Mineral Research, 2020, 36, 1316-1325.	3.1	3
46	Population-based study of autoimmune hepatitis and primary biliary cholangitis in Germany: rising prevalences based on ICD codes, yetÂdeficits in medical treatment. Zeitschrift Fur Gastroenterologie, 2020, 58, 431-438.	0.2	17
47	Aneurysm of the ascending aorta and dilation of the pulmonary trunk in a patient with homocysteinemia. Vasa - European Journal of Vascular Medicine, 2020, 49, 151-152.	0.6	0
48	CD49a Expression Identifies a Subset of Intrahepatic Macrophages in Humans. Frontiers in Immunology, 2019, 10, 1247.	2.2	11
49	LUCASÂ® leaving its footprints during cardiopulmonary resuscitation. Visual Journal of Emergency Medicine, 2019, 17, 100666.	0.0	2
50	Sex differences in clinical presentation and prognosis in patients with primary biliary cholangitis. Scandinavian Journal of Gastroenterology, 2019, 54, 1391-1396.	0.6	8
51	Clinical management of autoimmune hepatitis. United European Gastroenterology Journal, 2019, 7, 1156-1163.	1.6	42
52	Liver infiltrating T cells regulate bile acid metabolism in experimental cholangitis. Journal of Hepatology, 2019, 71, 783-792.	1.8	26
53	Interferon-Î³-dependent immune responses contribute to the pathogenesis of sclerosing cholangitis in mice. Journal of Hepatology, 2019, 71, 773-782.	1.8	30
54	The Translational Landscape of the Human Heart. Cell, 2019, 178, 242-260.e29.	13.5	407

#	Article	IF	Citations
55	Inflammatory Phenotype of Intrahepatic Sulfatide-Reactive Type II NKT Cells in Humans With Autoimmune Hepatitis. Frontiers in Immunology, 2019, 10, 1065.	2.2	16
56	Magnetic Resonance Imaging in Primary Sclerosing Cholangitisâ€"Current State and Future Directions. Seminars in Liver Disease, 2019, 39, 369-380.	1.8	17
57	Predniso(lo)ne Dosage and Chance of Remission in Patients With Autoimmune Hepatitis. Clinical Gastroenterology and Hepatology, 2019, 17, 2068-2075.e2.	2.4	55
58	Immunosuppression as effective therapy for eosinophilic cholangiopathy: A case series and review of the literature. GastroHep, 2019, 1, 33-44.	0.3	1
59	Human liverâ€derived CXCR6+NK cells are predominantly educated through NKG2A and show reduced cytokine production. Journal of Leukocyte Biology, 2019, 105, 1331-1340.	1.5	20
60	CCL21â€expression and accumulation of CCR7⁺ NK cells in livers of patients with primary sclerosing cholangitis. European Journal of Immunology, 2019, 49, 758-769.	1.6	18
61	Depression and anxiety in patients with different rare chronic diseases: A cross-sectional study. PLoS ONE, 2019, 14, e0211343.	1.1	55
62	Th17 cell frequency is associated with low bone mass in primary sclerosing cholangitis. Journal of Hepatology, 2019, 70, 941-953.	1.8	27
63	Sex-related factors in autoimmune liver diseases. Seminars in Immunopathology, 2019, 41, 165-175.	2.8	27
64	Disease Duration and Stage Influence Bone Microstructure in Patients With Primary Biliary Cholangitis. Journal of Bone and Mineral Research, 2018, 33, 1011-1019.	3.1	20
65	Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis. Journal of Hepatology, 2018, 68, 754-763.	1.8	90
66	A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. Hepatology, 2018, 67, 1890-1902.	3.6	204
67	Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. Gut, 2018, 67, 1517-1524.	6.1	42
68	Interactions Between KIR3DS1 and HLA-F Activate Natural Killer Cells to Control HCV Replication in Cell Culture. Gastroenterology, 2018, 155, 1366-1371.e3.	0.6	36
69	Bile Acids, the Microbiome, Immunity, and Liver Tumors. New England Journal of Medicine, 2018, 379, 888-890.	13.9	41
70	Tissue-resident NK cells differ in their expression profile of the nutrient transporters Glut1, CD98 and CD71. PLoS ONE, 2018, 13, e0201170.	1.1	46
71	Patients with primary biliary cholangitis and fatigue present with depressive symptoms and selected cognitive deficits, but with normal attention performance and brain structure. PLoS ONE, 2018, 13, e0190005.	1.1	11
72	Faecal microbiota profiles as diagnostic biomarkers in primary sclerosing cholangitis. Gut, 2017, 66, 753-754.	6.1	70

#	Article	IF	Citations
73	Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. Endoscopy, 2017, 49, 588-608.	1.0	154
74	norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. Journal of Hepatology, 2017, 67, 549-558.	1.8	202
75	Recommendations on the use of magnetic resonance imaging in PSCâ€A position statement from the International PSC Study Group. Hepatology, 2017, 66, 1675-1688.	3.6	104
76	Dysfunction of hepatic regulatory T cells in experimental sclerosing cholangitis is related to IL-12 signaling. Journal of Hepatology, 2017, 66, 798-805.	1.8	26
77	Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. Nature Genetics, 2017, 49, 269-273.	9.4	230
78	Role of ultrasound measuring position and ventilation pressure in determining correct tube size in children. Paediatric Anaesthesia, 2017, 27, 1241-1246.	0.6	6
79	Autoimmune hepatitisÂâ€"Âupdate on clinical management in 2017. Clinics and Research in Hepatology and Gastroenterology, 2017, 41, 617-625.	0.7	28
80	Metabolic Circuit Involving Free Fatty Acids, microRNA 122, and Triglyceride Synthesis in Liver and Muscle Tissues. Gastroenterology, 2017, 153, 1404-1415.	0.6	80
81	Proliferative capacity exhibited by human liver-resident CD49a+CD25+ NK cells. PLoS ONE, 2017, 12, e0182532.	1.1	27
82	Opposing role of tumor necrosis factor receptor 1 signaling in T cellâ€"mediated hepatitis and bacterial infection in mice. Hepatology, 2016, 64, 508-521.	3.6	21
83	Spleen size for the prediction of clinical outcome in patients with primary sclerosing cholangitis. Gut, 2016, 65, 1230-1232.	6.1	27
84	Biliary strictures and recurrence after liver transplantation for primary sclerosing cholangitis: A retrospective multicenter analysis. Liver Transplantation, 2016, 22, 42-52.	1.3	111
85	Reply. Clinical Gastroenterology and Hepatology, 2016, 14, 1063-1064.	2.4	0
86	Two Cases of Hepatosplenic T-Cell Lymphoma in Adolescents Treated for Autoimmune Hepatitis. Pediatrics, 2016, 138, .	1.0	8
87	Inflammation-Induced Expression and Secretion of MicroRNA 122 Leads to Reduced Blood Levels of Kidney-Derived Erythropoietin and Anemia. Gastroenterology, 2016, 151, 999-1010.e3.	0.6	53
88	No Evidence That Azathioprine Increases Risk ofÂCholangiocarcinoma in Patients With Primary SclerosingÂCholangitis. Clinical Gastroenterology and Hepatology, 2016, 14, 1806-1812.	2.4	15
89	Immunology of hepatic diseases during pregnancy. Seminars in Immunopathology, 2016, 38, 669-685.	2.8	19
90	Transient elastography in autoimmune hepatitis: Timing determines the impact of inflammation and fibrosis. Journal of Hepatology, 2016, 65, 769-775.	1.8	127

#	Article	IF	Citations
91	Acute Ebola virus disease patient treatment and health-related quality of life in health care professionals: A controlled study. Journal of Psychosomatic Research, 2016, 83, 69-74.	1.2	39
92	Efficacy of 6-Mercaptopurine as Second-Line Treatment forÂPatients With Autoimmune Hepatitis and Azathioprine Intolerance. Clinical Gastroenterology and Hepatology, 2016, 14, 445-453.	2.4	84
93	Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on Tacrolimus therapy. Scandinavian Journal of Gastroenterology, 2016, 51, 329-336.	0.6	53
94	Validation of Transient Elastography and Comparison with Spleen Length Measurement for Staging of Fibrosis and Clinical Prognosis in Primary Sclerosing Cholangitis. PLoS ONE, 2016, 11, e0164224.	1.1	45
95	Natural killer T cells: Novel players in biliary disease?. Hepatology, 2015, 62, 999-1000.	3.6	4
96	How Should Cancer Surveillance in Primary Sclerosing Cholangitis Be Performed?. Visceral Medicine, 2015, 31, 173-177.	0.5	3
97	Criteria Used in Clinical Practice to Guide Immunosuppressive Treatment in Patients with Primary Sclerosing Cholangitis. PLoS ONE, 2015, 10, e0140525.	1.1	8
98	24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis. Journal of Hepatology, 2015, 62, 871-878.	1.8	55
99	Nanoparticle-based autoantigen delivery to Treg-inducing liver sinusoidal endothelial cells enables control of autoimmunity in mice. Journal of Hepatology, 2015, 62, 1349-1356.	1.8	145
100	Testosterone Suppresses Hepatic Inflammation by the Downregulation of IL-17, CXCL-9, and CXCL-10 in a Mouse Model of Experimental Acute Cholangitis. Journal of Immunology, 2015, 194, 2522-2530.	0.4	50
101	PSC: Novel disease associations providing pathogenetic clues?. Journal of Hepatology, 2014, 60, 687-688.	1.8	1
102	Autoimmune hepatitis on the rise. Journal of Hepatology, 2014, 60, 478-479.	1.8	19
103	Genome-Wide Association Study Identifies Variants Associated With Autoimmune Hepatitis Type 1. Gastroenterology, 2014, 147, 443-452.e5.	0.6	268
104	Transient Elastography in Primary Sclerosing Cholangitisâ€"the Value as a Prognostic Factor and Limitations. Gastroenterology, 2014, 147, 542-543.	0.6	21
105	Reply to: â€œAnti-TNF-induced autoimmune hepatitisâ€• Journal of Hepatology, 2014, 61, 170-171.	1.8	2
106	TGF-Î²-dependent induction of CD4+CD25+Foxp3+ Tregs by liver sinusoidal endothelial cells. Journal of Hepatology, 2014, 61, 594-599.	1.8	185
107	Characterization of animal models for primary sclerosing cholangitis (PSC). Journal of Hepatology, 2014, 60, 1290-1303.	1.8	129
108	Low Risk of Hepatocellular Carcinoma in Patients With Primary Sclerosing Cholangitis With Cirrhosis. Clinical Gastroenterology and Hepatology, 2014, 12, 1733-1738.	2.4	66

#	Article	IF	Citations
109	Increased T helper type 17 response to pathogen stimulation in patients with primary sclerosing cholangitis. Hepatology, 2013, 58, 1084-1093.	3.6	132
110	Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nature Genetics, 2011, 43, 17-19.	9.4	221
111	Primary liver transplantation for autoimmune hepatitis: A comparative analysis of the European Liver Transplant Registry. Liver Transplantation, 2010, 16, NA-NA.	1.3	38
112	Genome-Wide Association Analysis in Primary Sclerosing Cholangitis. Gastroenterology, 2010, 138, 1102-1111.	0.6	325
113	Reply:. Hepatology, 2009, 49, 1783-1783.	3.6	0
114	Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology, 2008, 48, 169-176.	3.6	1,553
115	Pregnancy in Autoimmune Hepatitis: Outcome and Risk Factors. American Journal of Gastroenterology, 2006, 101, 556-560.	0.2	200